The FDA established a 'green list' import alert on September 5, 2025 to block GLP-1 active pharmaceutical ingredients from unverified foreign sources. Facilities inspected and found compliant will be listed, while all other GLP-1 APIs face detention without physical examination. The action targets the surge in illegal compounded semaglutide and tirzepatide, which the agency links to dosing errors and adverse events.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.